<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00401804</url>
  </required_header>
  <id_info>
    <org_study_id>Eudract Number: 2005-003001-85</org_study_id>
    <nct_id>NCT00401804</nct_id>
  </id_info>
  <brief_title>Bortezomib-Dexamethasone-Doxorubicin-Study</brief_title>
  <official_title>Bortezomib-Doxorubicin-Dexamethasone as Treatment for Patients With Multiple Myeloma Presenting With Acute Renal Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Austrian Forum Against Cancer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Austrian Forum Against Cancer</source>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the activity of BDD in subjects with acute
      renal failure as measured by· reversal of acute renal failureSecondary objectives· tumor
      response (complete and partial response)· To evaluate the safety of Bortezomib-
      Doxorubicin-Dexamethasone in this patient population· to evaluate the activity of Bortezomib-
      Doxorubicin -Dexamethasone on progression free survival · to evaluate the activity of
      Bortezomib- Doxorubicin -Dexamethasone on overall survival
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>OS</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>OR</measure>
  </secondary_outcome>
  <enrollment type="Actual">72</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Renal Insuficiency</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone, Bortezomib, Doxorubicin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of multiple myeloma ·

          -  Acute multiple myeloma related renal failure (Diagnosis established by clinical and
             laboratory findings including renal biopsy - if indicated)a) Newly diagnosed
             patients:Decrease of GFR to &lt; 50ml/minb) Previously treated patients with GFR of ≥
             60ml/min within last 4 weeks: decrease in GFR &gt; 25% and to &lt; 60ml / min,concomitantly
             with either increase in paraproteins (&gt;25%) and/or decrease in hemoglobin ≥ 2 g/dl
             (within 4 weeks) and/or increase in bone marrow plasma infiltration and/or increase in
             number of bone lesions and/or hypercalcaemia (Ca &gt; 11.5 mg/dl or 2.8 mmol/l) as signs
             of disease progression·

          -  Age &gt; 20 years·

          -  ECOG performance status of ≤ 3.·

          -  Platelet count &gt; 50.000/µl·

          -  WBC &gt; 2000/µl·

          -  Total bilirubin &lt; 1.5 x upper limit of normal,

          -  AST, ALT &lt; 2.5 x upper limit of normal·

          -  International Normalized Ratio (INR) &lt; 1.5; APTT &lt; 1.5 x upper limit of normal·

          -  Fertile women and men of childbearing potential (&lt;2 years after last menstruation in
             women) must use effective means of contraception (oral contraceptives, intrauterine
             contraceptive device, barrier method of contraception in conjunction with spermicidal
             jelly or surgically sterile)· Negative serum or urine β-HCG pregnancy test at
             screening for subjects of child-bearing potential·

          -  Patient's written informed consent

        Exclusion Criteria:

          -  History of malignancy other than squamous cell carcinoma, basal cell carcinoma of the
             skin or carcinoma in situ of the cervix within the last 5 years.·

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to study treatment start, or anticipation of the need for major surgical
             procedure during the course of the study.·

          -  Evidence of CNS involvement or spinal cord compression.·

          -  Neuropathy Grade ≥ 2·

          -  A history of uncontrolled seizures, central nervous system disorders or psychiatric
             disability judged by the investigator to be clinically significant and adversely
             affecting compliance to study drug.·

          -  NYHA Status &gt; 2, i.e. clinically significant cardiac disease, (congestive heart
             failure, symptomatic coronary artery disease, cardiac arrhythmias, and arterial
             hypertension not well controlled with medication) or myocardial infarction within the
             last 6 months ·

          -  Evidence of bleeding diathesis or coagulopathy·

          -  Serious, non-healing wound or ulcer·

          -  Evidence of any severe active acute or chronic infection.·

          -  Evidence of other disease, metabolic dysfunction, physical examination finding, or
             clinical laboratory finding giving reasonable suspicion of a disease or condition that
             contraindicates use of an investigational drug or patient at high risk from treatment
             complications·

          -  Patient is known to be HIV-positive, Hbs-antigen positive or HCV-RNA-positive·

          -  Pregnant women or nursing mothers·

          -  Have received bortezomib within 4 weeks before enrollment·

          -  Half body irradiation &lt; 28 days before enrollment·

          -  Has known or suspected hypersensitivity or intolerance to boron, mannitol, or heparin,
             if an indwelling catheter is used
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heinz Ludwig, MD, Univ.Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Austrian Forum agianst Cancer; Wilhelminenspital Vienna, 1st. Med. Department - center for Oncology and Hematology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Landeskrankenhaus Feldkirch</name>
      <address>
        <city>Feldkirch</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinischen Abteilung für Hämatologie, Medizinische Universitätsklinik Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Leoben</name>
      <address>
        <city>Leoben</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dep. of Internal Medicine I, Oncology, SALK - Gemeinnützige Salzburger Landeskliniken</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna, Dep. of Internal Medicine I</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Innere Medizin I</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilhelminenspital Vienna, 1st Med. Department - center for Oncology and Hematology</name>
      <address>
        <city>Vienna</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Kreuzschwestern Wels GmbH</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FN Brno Interni Hematoonkolog. klinika</name>
      <address>
        <city>Brno</city>
        <zip>62500</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czech Republic</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2006</study_first_submitted>
  <study_first_submitted_qc>November 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2006</study_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>renal impairment</keyword>
  <keyword>Velcade</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

